share_log

West Pharmaceutical Servs Analyst Ratings

West Pharmaceutical Servs Analyst Ratings

西部药业服务分析师评级
Benzinga ·  2023/10/27 11:31
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/27/2023 20.05% Stephens & Co. $420 → $390 Maintains Overweight
08/30/2023 35.45% Keybanc $415 → $440 Maintains Overweight
08/21/2023 27.75% Keybanc $385 → $415 Maintains Overweight
07/28/2023 18.51% Keybanc $375 → $385 Maintains Overweight
07/17/2023 29.29% Stephens & Co. $400 → $420 Maintains Overweight
06/16/2023 24.67% B of A Securities $390 → $405 Upgrades Neutral → Buy
04/11/2023 23.13% Stephens & Co. $330 → $400 Upgrades Equal-Weight → Overweight
02/17/2023 15.44% Keybanc $315 → $375 Maintains Overweight
12/14/2022 -23.04% Deutsche Bank → $250 Initiates Coverage On → Hold
12/02/2022 -3.03% Keybanc $350 → $315 Maintains Overweight
11/30/2022 -23.04% UBS → $250 Initiates Coverage On → Neutral
10/28/2022 -23.04% B of A Securities $385 → $250 Downgrades Buy → Neutral
10/28/2022 7.74% Keybanc $400 → $350 Maintains Overweight
07/29/2022 6.2% Stephens & Co. $330 → $345 Maintains Equal-Weight
04/29/2022 26.21% B of A Securities $475 → $410 Maintains Buy
04/29/2022 23.13% Keybanc $475 → $400 Maintains Overweight
09/15/2021 58.53% B of A Securities $450 → $515 Maintains Buy
07/30/2021 23.13% Stephens & Co. $360 → $400 Maintains Equal-Weight
07/30/2021 46.22% Keybanc $350 → $475 Maintains Overweight
04/30/2021 4.66% Stephens & Co. $315 → $340 Maintains Equal-Weight
02/19/2021 -3.03% Stephens & Co. $300 → $315 Maintains Equal-Weight
11/10/2020 7.74% Keybanc → $350 Initiates Coverage On → Overweight
10/14/2020 -7.65% Stephens & Co. → $300 Initiates Coverage On → Equal-Weight
04/24/2020 — B of A Securities Upgrades Underperform → Neutral
12/12/2019 — B of A Securities Downgrades Neutral → Underperform
07/26/2019 — B of A Securities Upgrades Underperform → Neutral
05/01/2019 — Jefferies Downgrades Buy → Hold
04/23/2019 — William Blair Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
2023年10月27日 20.05% 斯蒂芬斯公司 $420→$390 维护 超重
2023年08月30日 35.45% KeyBanc $415→$440 维护 超重
2023年08月21日 27.75% KeyBanc $385→$415 维护 超重
07/28/2023 18.51% KeyBanc $375→$385 维护 超重
07/17/2023 29.29% 斯蒂芬斯公司 $400→$420 维护 超重
06/16/2023 24.67% B of A证券 $390→$405 升级 中性→购买
04/11/2023 23.13% 斯蒂芬斯公司 $330→$400 升级 等重→超重
02/17/2023 15.44% KeyBanc $315→$375 维护 超重
2022年12月14日 -23.04% 德意志银行 →$250 开始承保 →保留
12/02/2022 -3.03% KeyBanc $350→$315 维护 超重
2022年11月30日 -23.04% 瑞银集团 →$250 开始承保 →中性
10/28/2022 -23.04% B of A证券 $385→$250 评级下调 购买→中性
10/28/2022 7.74% KeyBanc $400→$350 维护 超重
07/29/2022 6.2% 斯蒂芬斯公司 $330→$345 维护 等重
04/29/2022 26.21% B of A证券 $475→$410 维护 买
04/29/2022 23.13% KeyBanc $475→$400 维护 超重
2021/09/15 58.53% B of A证券 $450→$515 维护 买
07/30/2021 23.13% 斯蒂芬斯公司 $360→$400 维护 等重
07/30/2021 46.22% KeyBanc $350→$475 维护 超重
04/30/2021 4.66% 斯蒂芬斯公司 $315→$340 维护 等重
02/19/2021 -3.03% 斯蒂芬斯公司 $300→$315 维护 等重
11/10/2020 7.74% KeyBanc →$350 开始承保 →超重
10/14/2020 -7.65% 斯蒂芬斯公司 →$300 开始承保 →等重
04/24/2020 - B of A证券 升级 表现不佳的→中性
2019年12月12日 - B of A证券 评级下调 中性→表现不佳
2019年07月26日 - B of A证券 升级 表现不佳的→中性
2019年05月01日 - 杰富瑞 评级下调 购买→Hold
2019年04月23日 - 威廉·布莱尔 开始承保 →跑赢大盘

What is the target price for West Pharmaceutical Servs (WST)?

西部药业Serv(WST)的目标价格是多少？

The latest price target for West Pharmaceutical Servs (NYSE: WST) was reported by Stephens & Co. on October 27, 2023. The analyst firm set a price target for $390.00 expecting WST to rise to within 12 months (a possible 20.05% upside). 13 analyst firms have reported ratings in the last year.

West Pharmaceutical Servs（纽约证券交易所代码：WST）的最新目标价由Stephens & Co.于2023年10月27日公布。该分析公司将价格目标定为390.00美元，预计WST将在12个月内上涨（可能上涨20.05%）。去年有13家分析公司公布了评级。

What is the most recent analyst rating for West Pharmaceutical Servs (WST)?

西部药业Serv(WST)的最新分析师评级是多少？

The latest analyst rating for West Pharmaceutical Servs (NYSE: WST) was provided by Stephens & Co., and West Pharmaceutical Servs maintained their overweight rating.

对West Pharmtics Serv(纽约证券交易所代码：WST)的最新分析师评级是由Stephens&Co.提供的，West Pharmtics Serv维持其增持评级。

When is the next analyst rating going to be posted or updated for West Pharmaceutical Servs (WST)?

下一次分析师对西方制药服务公司(WST)的评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of West Pharmaceutical Servs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for West Pharmaceutical Servs was filed on October 27, 2023 so you should expect the next rating to be made available sometime around October 27, 2024.

分析师在做了广泛的研究后得出了股票评级，研究内容包括查阅公开财务报表、与西方制药服务公司的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月做一次，所以你每年应该对每家公司进行4次评级。West Pharmaceutical Servs的最后一次评级于2023年10月27日提交，因此您应该期待下一次评级将在2024年10月27日左右提供。

Is the Analyst Rating West Pharmaceutical Servs (WST) correct?

分析师对西方制药服务公司(WST)的评级正确吗？

While ratings are subjective and will change, the latest West Pharmaceutical Servs (WST) rating was a maintained with a price target of $420.00 to $390.00. The current price West Pharmaceutical Servs (WST) is trading at is $324.86, which is out of the analyst's predicted range.

虽然评级是主观的，会发生变化，但最新的West Pharmaceutical Servs（WST）评级维持在420.00美元至390.00美元的目标价格。West Pharmaceutical Servs（WST）目前的交易价格为324.86美元，超出了分析师的预测范围。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发